

# Magnus Ingelman-Sundberg

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5867950/magnus-ingelman-sundberg-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

360  
papers

23,792  
citations

83  
h-index

134  
g-index

392  
ext. papers

25,974  
ext. citations

5.5  
avg, IF

7.11  
L-index

#	Paper	IF	Citations
360	The polymorphic nuclear factor NFIB regulates hepatic CYP2D6 expression and influences risperidone metabolism in psychiatric patients.. <i>Clinical Pharmacology and Therapeutics</i> , <b>2022</b> ,	6.1	2
359	Hepatocyte Thorns, A Novel Drug-Induced Stress Response in Human and Mouse Liver Spheroids. <i>Cells</i> , <b>2022</b> , 11, 1597	7.9	
358	Cytochrome P450 polymorphism: From evolution to clinical use. <i>Advances in Pharmacology</i> , <b>2022</b> ,	5.7	
357	A Novel CYP2C-Haplotype Associated With Ultrarapid Metabolism of Escitalopram. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> , 110, 786-793	6.1	6
356	Evaluation of the CYP2D6 Haplotype Activity Scores Based on Metabolic Ratios of 4,700 Patients Treated With Three Different CYP2D6 Substrates. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> , 110, 750-758	6.1	4
355	3D human liver spheroids for translational pharmacology and toxicology. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2021</b> ,	3.1	7
354	. <i>Drug Metabolism and Disposition</i> , <b>2021</b> ,	4	8
353	Transcriptional and post-transcriptional regulation of the pregnane X receptor: a rationale for interindividual variability in drug metabolism. <i>Archives of Toxicology</i> , <b>2021</b> , 95, 11-25	5.8	4
352	Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure: A Systematic Review and Meta-analysis. <i>JAMA Psychiatry</i> , <b>2021</b> , 78, 270-280	14.5	33
351	Rates of complete nonadherence among atypical antipsychotic drugs: A study using blood samples from 13,217 outpatients with psychotic disorders. <i>Schizophrenia Research</i> , <b>2021</b> , 228, 590-596	3.6	6
350	CYP2E1 in Alcoholic and Non-Alcoholic Liver Injury. Roles of ROS, Reactive Intermediates and Lipid Overload. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	13
349	Toward predicting CYP2D6-mediated variable drug response from gene sequencing data. <i>Science Translational Medicine</i> , <b>2021</b> , 13,	17.5	9
348	Potential role of gut microbiota, the proto-oncogene PIKE (Agap2) and cytochrome P450 CYP2W1 in promotion of liver cancer by alcoholic and nonalcoholic fatty liver disease and protection by dietary soy protein. <i>Chemico-Biological Interactions</i> , <b>2020</b> , 325, 109131	5	3
347	Can CYP Inhibition Overcome Chemotherapy Resistance?. <i>Trends in Pharmacological Sciences</i> , <b>2020</b> , 41, 503-506	13.2	7
346	Emerging strategies to bridge the gap between pharmacogenomic research and its clinical implementation. <i>Npj Genomic Medicine</i> , <b>2020</b> , 5, 9	6.2	24
345	Human Liver Spheroids as a Model to Study Aetiology and Treatment of Hepatic Fibrosis. <i>Cells</i> , <b>2020</b> , 9,	7.9	25
344	Clinically Relevant Cytochrome P450 3A4 Induction Mechanisms and Drug Screening in Three-Dimensional Spheroid Cultures of Primary Human Hepatocytes. <i>Clinical Pharmacology and Therapeutics</i> , <b>2020</b> , 108, 844-855	6.1	12

343	Impact of CYP2C19 genotype on sertraline exposure in 1200 Scandinavian patients. <i>Neuropsychopharmacology</i> , <b>2020</b> , 45, 570-576	8.7	18
342	Evaluation of Current Regulation and Guidelines of Pharmacogenomic Drug Labels: Opportunities for Improvements. <i>Clinical Pharmacology and Therapeutics</i> , <b>2020</b> , 107, 1240-1255	6.1	25
341	Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models. <i>Nature Reviews Drug Discovery</i> , <b>2020</b> , 19, 131-148	64.1	82
340	Pharmacogenetics in Psychiatry: An Update on Clinical Usability. <i>Frontiers in Pharmacology</i> , <b>2020</b> , 11, 575540	5.6	23
339	A 3D Cell Culture Model Identifies Wnt/-Catenin Mediated Inhibition of p53 as a Critical Step during Human Hepatocyte Regeneration. <i>Advanced Science</i> , <b>2020</b> , 7, 2000248	13.6	17
338	Impact of antipsychotic polypharmacy on nonadherence of oral antipsychotic drugs - A study based on blood sample analyses from 24,239 patients. <i>European Neuropsychopharmacology</i> , <b>2020</b> , 37, 64-69	1.2	4
337	Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study. <i>Pharmacogenetics and Genomics</i> , <b>2020</b> , 30, 131-144	1.9	10
336	Pharmacogenomics of Antidepressant and Antipsychotic Treatment: How Far Have We Got and Where Are We Going?. <i>Frontiers in Psychiatry</i> , <b>2020</b> , 11, 94	5	40
335	Mechanisms of chronic fialuridine hepatotoxicity as revealed in primary human hepatocyte spheroids. <i>Toxicological Sciences</i> , <b>2019</b> ,	4.4	12
334	IMPACT OF CYP GENOTYPE ON THE SUCCESS OF ANTIDEPRESSANT THERAPY. <i>European Neuropsychopharmacology</i> , <b>2019</b> , 29, S1030	1.2	
333	Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity. <i>Pharmacology &amp; Therapeutics</i> , <b>2019</b> , 197, 122-152	13.9	41
332	Prediction of drug response and adverse drug reactions: From twin studies to Next Generation Sequencing. <i>European Journal of Pharmaceutical Sciences</i> , <b>2019</b> , 130, 65-77	5.1	30
331	Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study. <i>Lancet Psychiatry</i> , <b>2019</b> , 6, 418-426	23.3	60
330	Development of the PGx-Passport: A Panel of Actionable Germline Genetic Variants for Pre-Emptive Pharmacogenetic Testing. <i>Clinical Pharmacology and Therapeutics</i> , <b>2019</b> , 106, 866-873	6.1	43
329	3D Primary Hepatocyte Culture Systems for Analyses of Liver Diseases, Drug Metabolism, and Toxicity: Emerging Culture Paradigms and Applications. <i>Biotechnology Journal</i> , <b>2019</b> , 14, e1800347	5.6	59
328	The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids. <i>Scientific Reports</i> , <b>2019</b> , 9, 11585	4.9	44
327	4th ESPT Conference: pharmacogenomics and personalized medicine— research progress and clinical implementation. <i>Pharmacogenomics</i> , <b>2019</b> , 20, 1063-1069	2.6	1
326	CYP3A5 is unlikely to mediate anticancer drug resistance in hepatocellular carcinoma. <i>Pharmacogenomics</i> , <b>2019</b> , 20, 1085-1092	2.6	1

325	One non-believer: Response to "Obviously Nine Believers: Actionable Germline Genetic Variants for Pre-emptive Pharmacogenetic Testing". <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2019</b> , 126, 7	3.1	0
324	AMP-activated protein kinase activation and NADPH oxidase inhibition by inorganic nitrate and nitrite prevent liver steatosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2019</b> , 116, 217-226	11.5	46
323	Characterisation of the NRF2 transcriptional network and its response to chemical insult in primary human hepatocytes: implications for prediction of drug-induced liver injury. <i>Archives of Toxicology</i> , <b>2019</b> , 93, 385-399	5.8	18
322	Significantly lower CYP2D6 metabolism measured as the O/N-desmethylvenlafaxine metabolic ratio in carriers of CYP2D6*41 versus CYP2D6*9 or CYP2D6*10: a study on therapeutic drug monitoring data from 1003 genotyped Scandinavian patients. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 194-201	3.8	18
321	Prediction of Drug-Induced Hepatotoxicity Using Long-Term Stable Primary Hepatic 3D Spheroid Cultures in Chemically Defined Conditions. <i>Toxicological Sciences</i> , <b>2018</b> , 163, 655-665	4.4	98
320	Impact of CYP2C19 Genotype on Escitalopram Exposure and Therapeutic Failure: A Retrospective Study Based on 2,087 Patients. <i>American Journal of Psychiatry</i> , <b>2018</b> , 175, 463-470	11.9	75
319	Comparison of Hepatic 2D Sandwich Cultures and 3D Spheroids for Long-term Toxicity Applications: A Multicenter Study. <i>Toxicological Sciences</i> , <b>2018</b> , 162, 655-666	4.4	158
318	How to Consider Rare Genetic Variants in Personalized Drug Therapy. <i>Clinical Pharmacology and Therapeutics</i> , <b>2018</b> , 103, 745-748	6.1	27
317	Novel copy-number variations in pharmacogenes contribute to interindividual differences in drug pharmacokinetics. <i>Genetics in Medicine</i> , <b>2018</b> , 20, 622-629	8.1	44
316	Pharmacoepigenetics and Toxicopigenetics: Novel Mechanistic Insights and Therapeutic Opportunities. <i>Annual Review of Pharmacology and Toxicology</i> , <b>2018</b> , 58, 161-185	17.9	36
315	Application of Microphysiological Systems to Enhance Safety Assessment in Drug Discovery. <i>Annual Review of Pharmacology and Toxicology</i> , <b>2018</b> , 58, 65-82	17.9	83
314	Integrating rare genetic variants into pharmacogenetic drug response predictions. <i>Human Genomics</i> , <b>2018</b> , 12, 26	6.8	99
313	Human liver spheroids in chemically defined conditions for studies of gene-drug, drug-drug and disease-drug interactions. <i>Pharmacogenomics</i> , <b>2018</b> , 19, 1133-1138	2.6	12
312	Functional characterization of CYP2D7 gene variants. <i>Pharmacogenomics</i> , <b>2018</b> , 19, 931-936	2.6	0
311	Three-Dimensional Spheroid Primary Human Hepatocytes in Monoculture and Coculture with Nonparenchymal Cells. <i>Tissue Engineering - Part C: Methods</i> , <b>2018</b> , 24, 534-545	2.9	45
310	Inter-individual differences in the susceptibility of primary human hepatocytes towards drug-induced cholestasis are compound and time dependent. <i>Toxicology Letters</i> , <b>2018</b> , 295, 187-194	4.4	15
309	Prediction of drug-induced hepatotoxicity using long-term stable primary hepatic 3D spheroid cultures. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , <b>2018</b> , WCP2018, PO4-9-16		
308	Transcriptomic, Proteomic, and Functional Long-Term Characterization of Multicellular Three-Dimensional Human Liver Microtissues. <i>Applied in Vitro Toxicology</i> , <b>2018</b> , 4, 1-12	1.3	34

307	The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the Human Cytochrome P450 (CYP) Allele Nomenclature Database. <i>Clinical Pharmacology and Therapeutics</i> , <b>2018</b> , 103, 399-401	6.1	201
306	Human hepatic 3D spheroids as a model for steatosis and insulin resistance. <i>Scientific Reports</i> , <b>2018</b> , 8, 14297	4.9	72
305	Current Statistical Metrics Are Pragmatic Measures to Compare the Predictive Quality of Preclinical Assays. <i>Toxicological Sciences</i> , <b>2018</b> , 165, 4-5	4.4	4
304	Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response. <i>Genetics in Medicine</i> , <b>2017</b> , 19, 20-29	8.1	124
303	Transcriptional, Functional, and Mechanistic Comparisons of Stem Cell-Derived Hepatocytes, HepaRG Cells, and Three-Dimensional Human Hepatocyte Spheroids as Predictive In Vitro Systems for Drug-Induced Liver Injury. <i>Drug Metabolism and Disposition</i> , <b>2017</b> , 45, 419-429	4	108
302	Endogenous and xenobiotic metabolic stability of primary human hepatocytes in long-term 3D spheroid cultures revealed by a combination of targeted and untargeted metabolomics. <i>FASEB Journal</i> , <b>2017</b> , 31, 2696-2708	0.9	90
301	Pitfalls and Opportunities for Epigenomic Analyses Focused on Disease Diagnosis, Prognosis, and Therapy. <i>Trends in Pharmacological Sciences</i> , <b>2017</b> , 38, 765-770	13.2	7
300	Regulation of drug metabolism and toxicity by multiple factors of genetics, epigenetics, lncRNAs, gut microbiota, and diseases: a meeting report of the 21 International Symposium on Microsomes and Drug Oxidations (MDO). <i>Acta Pharmaceutica Sinica B</i> , <b>2017</b> , 7, 241-248	15.5	17
299	The role of microRNAs in liver injury at the crossroad between hepatic cell death and regeneration. <i>Biochemical and Biophysical Research Communications</i> , <b>2017</b> , 482, 399-407	3.4	20
298	Stem cell-derived models to improve mechanistic understanding and prediction of human drug-induced liver injury. <i>Hepatology</i> , <b>2017</b> , 65, 710-721	11.2	47
297	A multicenter assessment of single-cell models aligned to standard measures of cell health for prediction of acute hepatotoxicity. <i>Archives of Toxicology</i> , <b>2017</b> , 91, 1385-1400	5.8	71
296	Pharmacogenomic Biomarkers for Improved Drug Therapy-Recent Progress and Future Developments. <i>AAPS Journal</i> , <b>2017</b> , 20, 4	3.7	78
295	Massive rearrangements of cellular MicroRNA signatures are key drivers of hepatocyte dedifferentiation. <i>Hepatology</i> , <b>2016</b> , 64, 1743-1756	11.2	69
294	Evidence-based selection of training compounds for use in the mechanism-based integrated prediction of drug-induced liver injury in man. <i>Archives of Toxicology</i> , <b>2016</b> , 90, 2979-3003	5.8	34
293	Requirements for comprehensive pharmacogenetic genotyping platforms. <i>Pharmacogenomics</i> , <b>2016</b> , 17, 917-24	2.6	30
292	The CYP2W1 enzyme: regulation, properties and activation of prodrugs. <i>Drug Metabolism Reviews</i> , <b>2016</b> , 48, 369-78	7	12
291	Precision Medicine and Rare Genetic Variants. <i>Trends in Pharmacological Sciences</i> , <b>2016</b> , 37, 85-86	13.2	47
290	High Content Analysis of Human Pluripotent Stem Cell Derived Hepatocytes Reveals Drug Induced Steatosis and Phospholipidosis. <i>Stem Cells International</i> , <b>2016</b> , 2016, 2475631	5	24

289	The Importance of Patient-Specific Factors for Hepatic Drug Response and Toxicity. <i>International Journal of Molecular Sciences</i> , <b>2016</b> , 17,	6.3	56
288	Human Cytochrome P450 2W1 Is Not Expressed in Adrenal Cortex and Is Only Rarely Expressed in Adrenocortical Carcinomas. <i>PLoS ONE</i> , <b>2016</b> , 11, e0162379	3.7	6
287	Pharmacogenomic or -epigenomic biomarkers in drug treatment: Two sides of the same medal?. <i>Clinical Pharmacology and Therapeutics</i> , <b>2016</b> , 99, 478-80	6.1	16
286	Membrane topology and search for potential redox partners of colon cancer-specific cytochrome P450 2W1. <i>FEBS Letters</i> , <b>2016</b> , 590, 330-9	3.8	9
285	Hepatic 3D spheroid models for the detection and study of compounds with cholestatic liability. <i>Scientific Reports</i> , <b>2016</b> , 6, 35434	4.9	93
284	Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease. <i>Scientific Reports</i> , <b>2016</b> , 6, 25187	4.9	385
283	Single base resolution analysis of 5-hydroxymethylcytosine in 188 human genes: implications for hepatic gene expression. <i>Nucleic Acids Research</i> , <b>2016</b> , 44, 6756-69	20.1	14
282	Novel 3D Culture Systems for Studies of Human Liver Function and Assessments of the Hepatotoxicity of Drugs and Drug Candidates. <i>Chemical Research in Toxicology</i> , <b>2016</b> , 29, 1936-1955	4	153
281	Comparative Proteomic Characterization of 4 Human Liver-Derived Single Cell Culture Models Reveals Significant Variation in the Capacity for Drug Disposition, Bioactivation, and Detoxication. <i>Toxicological Sciences</i> , <b>2015</b> , 147, 412-24	4.4	61
280	Mechanism-Based Markers of Drug-Induced Liver Injury to Improve the Physiological Relevance and Predictivity of In Vitro Models. <i>Applied in Vitro Toxicology</i> , <b>2015</b> , 1, 175-186	1.3	5
279	Role of cytochrome P450 2C8*3 (CYP2C8*3) in paclitaxel metabolism and paclitaxel-induced neurotoxicity. <i>Pharmacogenomics</i> , <b>2015</b> , 16, 929-37	2.6	14
278	Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity-implications for therapeutic targeting of Nrf2. <i>Free Radical Biology and Medicine</i> , <b>2015</b> , 78, 202-12	7.8	131
277	Whole-exome sequencing reveals defective CYP3A4 variants predictive of paclitaxel dose-limiting neuropathy. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 322-8	12.9	49
276	Personalized medicine into the next generation. <i>Journal of Internal Medicine</i> , <b>2015</b> , 277, 152-154	10.8	11
275	Cytostatic Effect of Repeated Exposure to Simvastatin: A Mechanism for Chronic Myotoxicity Revealed by the Use of Mesodermal Progenitors Derived from Human Pluripotent Stem Cells. <i>Stem Cells</i> , <b>2015</b> , 33, 2936-48	5.8	10
274	Genetic variation in the human cytochrome P450 supergene family. <i>Pharmacogenetics and Genomics</i> , <b>2015</b> , 25, 584-94	1.9	99
273	Developmental regulation and induction of cytochrome P450 2W1, an enzyme expressed in colon tumors. <i>PLoS ONE</i> , <b>2015</b> , 10, e0122820	3.7	14
272	Expression and Function of mARC: Roles in Lipogenesis and Metabolic Activation of Ximelagatran. <i>PLoS ONE</i> , <b>2015</b> , 10, e0138487	3.7	16

271	Stem cell-derived systems in toxicology assessment. <i>Stem Cells and Development</i> , <b>2015</b> , 24, 1284-96	4.4	41
270	Long-term chronic toxicity testing using human pluripotent stem cell-derived hepatocytes. <i>Drug Metabolism and Disposition</i> , <b>2014</b> , 42, 1401-6	4	73
269	High CYP2A6 enzyme activity as measured by a caffeine test and unique distribution of CYP2A6 variant alleles in Ethiopian population. <i>OMICS A Journal of Integrative Biology</i> , <b>2014</b> , 18, 446-53	3.8	20
268	Epigenetic mechanisms of importance for drug treatment. <i>Trends in Pharmacological Sciences</i> , <b>2014</b> , 35, 384-96	13.2	112
267	Genetic and epigenetic regulation of gene expression in fetal and adult human livers. <i>BMC Genomics</i> , <b>2014</b> , 15, 860	4.5	90
266	The expression of CYP2W1 in colorectal primary tumors, corresponding lymph node metastases and liver metastases. <i>Acta Oncologica</i> , <b>2014</b> , 53, 885-91	3.2	13
265	Re-engineering of the duocarmycin structural architecture enables bioprecursor development targeting CYP1A1 and CYP2W1 for biological activity. <i>Journal of Medicinal Chemistry</i> , <b>2013</b> , 56, 6273-7	8.3	28
264	CYP2W1 polymorphism: functional aspects and relation to risk for colorectal cancer. <i>Pharmacogenomics</i> , <b>2013</b> , 14, 1615-22	2.6	9
263	3D organotypic cultures of human HepaRG cells: a tool for in vitro toxicity studies. <i>Toxicological Sciences</i> , <b>2013</b> , 133, 67-78	4.4	172
262	Ontogeny, distribution and potential roles of 5-hydroxymethylcytosine in human liver function. <i>Genome Biology</i> , <b>2013</b> , 14, R83	18.3	54
261	Induced CYP3A4 expression in confluent Huh7 hepatoma cells as a result of decreased cell proliferation and subsequent pregnane X receptor activation. <i>Molecular Pharmacology</i> , <b>2013</b> , 83, 659-704 <sup>3</sup>	4.3	28
260	Potential role of epigenetic mechanisms in the regulation of drug metabolism and transport. <i>Drug Metabolism and Disposition</i> , <b>2013</b> , 41, 1725-31	4	57
259	Strong effects of environmental factors on prevalence and course of major depressive disorder are not moderated by 5-HTTLPR polymorphisms in a large Dutch sample. <i>Journal of Affective Disorders</i> , <b>2013</b> , 146, 91-9	6.6	23
258	Characterization of human cytochrome P450s involved in the bioactivation of clozapine. <i>Drug Metabolism and Disposition</i> , <b>2013</b> , 41, 651-8	4	38
257	Update on allele nomenclature for human cytochromes P450 and the Human Cytochrome P450 Allele (CYP-allele) Nomenclature Database. <i>Methods in Molecular Biology</i> , <b>2013</b> , 987, 251-9	1.4	61
256	An integrated in vitro model for simultaneous assessment of drug uptake, metabolism, and efflux. <i>Molecular Pharmaceutics</i> , <b>2013</b> , 10, 3152-63	5.6	11
255	Hepatic differentiation and maturation of human embryonic stem cells cultured in a perfused three-dimensional bioreactor. <i>Stem Cells and Development</i> , <b>2013</b> , 22, 581-94	4.4	52
254	Colon cancer-specific cytochrome P450 2W1 converts duocarmycin analogues into potent tumor cytotoxins. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 2952-61	12.9	40

253	In-solution hybrid capture of bisulfite-converted DNA for targeted bisulfite sequencing of 174 ADME genes. <i>Nucleic Acids Research</i> , <b>2013</b> , 41, e72	20.1	38
252	Sex difference in formation of propofol metabolites: a replication study. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2013</b> , 113, 126-31	3.1	34
251	Epigenomics and interindividual differences in drug response. <i>Clinical Pharmacology and Therapeutics</i> , <b>2012</b> , 92, 727-36	6.1	92
250	DNA methylation dynamics in the hepatic CYP3A4 gene promoter. <i>Biochimie</i> , <b>2012</b> , 94, 2338-44	4.6	46
249	Epigenetic-dependent regulation of drug transport and metabolism: an update. <i>Pharmacogenomics</i> , <b>2012</b> , 13, 1373-85	2.6	32
248	Omeprazole limited sampling strategies to predict area under the concentration-time curve ratios: implications for cytochrome P450 2C19 and 3A phenotyping. <i>European Journal of Clinical Pharmacology</i> , <b>2012</b> , 68, 407-13	2.8	7
247	Influence of sex on propofol metabolism, a pilot study: implications for propofol anesthesia. <i>European Journal of Clinical Pharmacology</i> , <b>2012</b> , 68, 397-406	2.8	52
246	Amidoxime reductase system containing cytochrome b5 type B (CYB5B) and MOSC2 is of importance for lipid synthesis in adipocyte mitochondria. <i>Journal of Biological Chemistry</i> , <b>2012</b> , 287, 6307-17	5.4	42
245	Institutional profile: Karolinska Institutet. <i>Pharmacogenomics</i> , <b>2012</b> , 13, 1887-91	2.6	1
244	CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP. <i>Journal of Psychopharmacology</i> , <b>2012</b> , 26, 398-407	4.6	52
243	The expression of CYP2W1: a prognostic marker in colon cancer. <i>Anticancer Research</i> , <b>2012</b> , 32, 3869-74	2.3	30
242	Pharmacogenomic biomarkers: new tools in current and future drug therapy. <i>Trends in Pharmacological Sciences</i> , <b>2011</b> , 32, 72-81	13.2	78
241	Toward preclinical predictive drug testing for metabolism and hepatotoxicity by using in vitro models derived from human embryonic stem cells and human cell lines - a report on the Vitrocellomics EU-project. <i>ATLA Alternatives To Laboratory Animals</i> , <b>2011</b> , 39, 147-71	2.1	34
240	Perspectives on epigenetics and its relevance to adverse drug reactions. <i>Clinical Pharmacology and Therapeutics</i> , <b>2011</b> , 89, 902-7	6.1	50
239	Databases in the area of pharmacogenetics. <i>Human Mutation</i> , <b>2011</b> , 32, 526-31	4.7	38
238	The ligands of estrogen receptor $\beta$ regulate cytochrome P4502C9 (CYP2C9) expression. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2011</b> , 338, 302-9	4.7	17
237	Human embryonic stem cell derived hepatocyte-like cells as a tool for in vitro hazard assessment of chemical carcinogenicity. <i>Toxicological Sciences</i> , <b>2011</b> , 124, 278-90	4.4	55
236	Genetic polymorphism and toxicology--with emphasis on cytochrome p450. <i>Toxicological Sciences</i> , <b>2011</b> , 120, 1-13	4.4	185



235	CYP3A4 catalytic activity is induced in confluent Huh7 hepatoma cells. <i>Drug Metabolism and Disposition</i> , <b>2010</b> , 38, 995-1002	4	47
234	New insights into the regulation of CYP2C9 gene expression: the role of the transcription factor GATA-4. <i>Drug Metabolism and Disposition</i> , <b>2010</b> , 38, 415-21	4	22
233	Regulation of CYP2C19 expression by estrogen receptor $\beta$ : implications for estrogen-dependent inhibition of drug metabolism. <i>Molecular Pharmacology</i> , <b>2010</b> , 78, 886-94	4.3	46
232	Colorectal cancer-specific cytochrome P450 2W1: intracellular localization, glycosylation, and catalytic activity. <i>Molecular Pharmacology</i> , <b>2010</b> , 78, 1004-11	4.3	33
231	Breaking self-tolerance toward cytochrome P4502E1 (CYP2E1) in chronic hepatitis C: possible role for molecular mimicry. <i>Journal of Hepatology</i> , <b>2010</b> , 53, 431-8	13.4	14
230	The transcription factor GATA-4 regulates cytochrome P4502C19 gene expression. <i>Life Sciences</i> , <b>2010</b> , 86, 699-706	6.8	21
229	Pharmacogenetic biomarkers as tools for improved drug therapy; emphasis on the cytochrome P450 system. <i>Biochemical and Biophysical Research Communications</i> , <b>2010</b> , 396, 90-4	3.4	52
228	Hepatic drug metabolizing profile of Flinders Sensitive Line rat model of depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2010</b> , 34, 1075-84	5.5	8
227	The past, present and future of pharmacoepigenomics. <i>Pharmacogenomics</i> , <b>2010</b> , 11, 625-7	2.6	49
226	Intronic polymorphisms of cytochromes P450. <i>Human Genomics</i> , <b>2010</b> , 4, 402-5	6.8	18
225	CYP2C19 activity comparison between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking. <i>European Journal of Clinical Pharmacology</i> , <b>2010</b> , 66, 871-7	2.8	45
224	Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations. <i>European Journal of Clinical Pharmacology</i> , <b>2010</b> , 66, 1199-205	2.8	68
223	Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment. <i>Human Genetics</i> , <b>2010</b> , 127, 1-17	6.3	91
222	IL-4-mediated transcriptional regulation of human CYP2E1 by two independent signaling pathways. <i>Biochemical Pharmacology</i> , <b>2010</b> , 80, 1592-600	6	19
221	Association between CYP2C19 polymorphism and depressive symptoms. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , <b>2010</b> , 153B, 1160-6	3.5	20
220	Hepatocyte-like cells derived from human embryonic stem cells specifically via definitive endoderm and a progenitor stage. <i>Journal of Biotechnology</i> , <b>2010</b> , 145, 284-94	3.7	99
219	Cytochrome P450 proteins: retention and distribution from the endoplasmic reticulum. <i>Current Opinion in Drug Discovery &amp; Development</i> , <b>2010</b> , 13, 78-85		23
218	Pharmacoepigenetic aspects of gene polymorphism on drug therapies: effects of DNA methylation on drug response. <i>Expert Review of Clinical Pharmacology</i> , <b>2009</b> , 2, 55-65	3.8	4

217	Xenobiotic-metabolizing enzymes and transporters in the normal human brain: regional and cellular mapping as a basis for putative roles in cerebral function. <i>Drug Metabolism and Disposition</i> , <b>2009</b> , 37, 1528-38	4	128
216	Regulation of human CYP2C18 and CYP2C19 in transgenic mice: influence of castration, testosterone, and growth hormone. <i>Drug Metabolism and Disposition</i> , <b>2009</b> , 37, 1505-12	4	21
215	In silico platform for xenobiotics ADME-T pharmacological properties modeling and prediction. Part I: Beyond the reduction of animal model use. <i>Drug Discovery Today</i> , <b>2009</b> , 14, 401-5	8.8	14
214	Pharmacoeigenetics: its role in interindividual differences in drug response. <i>Clinical Pharmacology and Therapeutics</i> , <b>2009</b> , 85, 426-30	6.1	84
213	The expression of the novel CYP2W1 enzyme is an independent prognostic factor in colorectal cancer - a pilot study. <i>European Journal of Cancer</i> , <b>2009</b> , 45, 705-12	7.5	36
212	Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. <i>Toxicology in Vitro</i> , <b>2009</b> , 23, 1387-95	3.6	33
211	The impact of CYP2E1 on the development of alcoholic liver disease as studied in a transgenic mouse model. <i>Journal of Hepatology</i> , <b>2009</b> , 50, 572-83	13.4	76
210	Epigenetic and microRNA-dependent control of cytochrome P450 expression: a gap between DNA and protein. <i>Pharmacogenomics</i> , <b>2009</b> , 10, 1067-76	2.6	44
209	Allele-specific expression and gene methylation in the control of CYP1A2 mRNA level in human livers. <i>Pharmacogenomics Journal</i> , <b>2009</b> , 9, 208-17	3.5	47
208	Nomenclature for alleles of the cytochrome P450 oxidoreductase gene. <i>Pharmacogenetics and Genomics</i> , <b>2009</b> , 19, 565-6	1.9	26
207	Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , <b>2008</b> , 65, 767-74	3.8	119
206	Inhibition of CYP2E1 Activity does not Abolish Pulsatile Urine Alcohol Concentrations During Chronic Alcohol Infusions. <i>FEBS Journal</i> , <b>2008</b> , 230, 914-919		
205	Pharmacogenomic biomarkers for prediction of severe adverse drug reactions. <i>New England Journal of Medicine</i> , <b>2008</b> , 358, 637-9	59.2	111
204	Pro-inflammatory response and adverse drug reactions: mechanisms of action of ximelagatran on chemokine and cytokine activation in a monocyte in vitro model. <i>Toxicology in Vitro</i> , <b>2008</b> , 22, 1588-94	3.6	12
203	Cytokine and chemokine expression associated with steatohepatitis and hepatocyte proliferation in rats fed ethanol via total enteral nutrition. <i>Experimental Biology and Medicine</i> , <b>2008</b> , 233, 344-55	3.7	56
202	Generation of mice transgenic for human CYP2C18 and CYP2C19: characterization of the sexually dimorphic gene and enzyme expression. <i>Drug Metabolism and Disposition</i> , <b>2008</b> , 36, 955-62	4	38
201	CYP1A1, GSTM1, and GSTT1 polymorphisms, smoking, and lung cancer risk in a pooled analysis among Asian populations. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2008</b> , 17, 1120-6	4	50
200	Intracellular transport and localization of microsomal cytochrome P450. <i>Analytical and Bioanalytical Chemistry</i> , <b>2008</b> , 392, 1075-84	4.4	47

199	Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects. <i>European Journal of Clinical Pharmacology</i> , <b>2008</b> , 64, 1175-9	2.8	53
198	Mutations in CYP1B1 cause primary congenital glaucoma by reduction of either activity or abundance of the enzyme. <i>Human Mutation</i> , <b>2008</b> , 29, 1147-53	4.7	58
197	Expression of CYP2W1 in colon tumors: regulation by gene methylation. <i>Pharmacogenomics</i> , <b>2007</b> , 8, 1315-25	2.6	55
196	Glutamate activates c-fos in glial cells via a novel mechanism involving the glutamate receptor subtype mGlu5 and the transcriptional repressor DREAM. <i>Glia</i> , <b>2007</b> , 55, 328-40	9	48
195	Expression of drug metabolizing enzymes in hepatocyte-like cells derived from human embryonic stem cells. <i>Biochemical Pharmacology</i> , <b>2007</b> , 74, 496-503	6	85
194	Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigentic and clinical aspects <b>2007</b> , 116, 496-526		848
193	Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. <i>European Journal of Clinical Pharmacology</i> , <b>2007</b> , 63, 537-46	2.8	193
192	Characterization of the novel defective CYP2C9*24 allele. <i>Drug Metabolism and Disposition</i> , <b>2007</b> , 35, 831-4	4	6
191	Calcium-regulating peptide hormones and blood electrolytic balance in chronic heart failure. <i>Regulatory Peptides</i> , <b>2007</b> , 142, 95-100		15
190	3QTR polymorphism in the human CYP2A6 gene affects mRNA stability and enzyme expression. <i>Biochemical and Biophysical Research Communications</i> , <b>2006</b> , 340, 491-7	3.4	76
189	Tumor-specific expression of the novel cytochrome P450 enzyme, CYP2W1. <i>Biochemical and Biophysical Research Communications</i> , <b>2006</b> , 341, 451-8	3.4	90
188	Metabolism: a bottleneck in in vitro toxicological test development. The report and recommendations of ECVAM workshop 54. <i>ATLA Alternatives To Laboratory Animals</i> , <b>2006</b> , 34, 49-84	2.1	124
187	Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. <i>Pharmacogenetics and Genomics</i> , <b>2006</b> , 16, 191-8	1.9	126
186	Search for an association between the human CYP1A2 genotype and CYP1A2 metabolic phenotype. <i>Pharmacogenetics and Genomics</i> , <b>2006</b> , 16, 359-67	1.9	75
185	A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. <i>Clinical Pharmacology and Therapeutics</i> , <b>2006</b> , 79, 103-13	6.1	523
184	Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity. <i>Clinical Pharmacology and Therapeutics</i> , <b>2006</b> , 79, 339-49	6.1	83
183	Pharmacogenomics and individualized drug therapy. <i>Annual Review of Medicine</i> , <b>2006</b> , 57, 119-37	17.4	486
182	Common polymorphisms in the CYP7A1 gene do not contribute to variation in rates of bile acid synthesis and plasma LDL cholesterol concentration. <i>Atherosclerosis</i> , <b>2005</b> , 182, 37-45	3.1	18

181	Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. <i>Biochemical and Biophysical Research Communications</i> , <b>2005</b> , 338, 299-305	3.4	85
180	Role of the conserved threonine 309 in mechanism of oxidation by cytochrome P450 2D6. <i>Biochemical and Biophysical Research Communications</i> , <b>2005</b> , 338, 1065-74	3.4	33
179	Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles. <i>Toxicology in Vitro</i> , <b>2005</b> , 19, 621-9	3.6	47
178	CYP3A7 protein expression is high in a fraction of adult human livers and partially associated with the CYP3A7*1C allele. <i>Pharmacogenetics and Genomics</i> , <b>2005</b> , 15, 625-31	1.9	75
177	Identification and phenotype characterization of two CYP3A haplotypes causing different enzymatic capacity in fetal livers. <i>Clinical Pharmacology and Therapeutics</i> , <b>2005</b> , 77, 259-70	6.1	46
176	Activation of c-fos by lipopolysaccharide in glial cells via p38 mitogen-activated protein kinase-dependent activation of serum or cyclic AMP/calcium response element. <i>Journal of Neurochemistry</i> , <b>2005</b> , 92, 915-24	6	15
175	Modulation of Oxidative Stress by Alcohol. <i>Alcoholism: Clinical and Experimental Research</i> , <b>2005</b> , 29, 1060-1065	5.4	4
174	Regulation of aryl hydrocarbon receptor signal transduction by protein tyrosine kinases. <i>Cellular Signalling</i> , <b>2005</b> , 17, 39-48	4.9	85
173	Effects of N-acetylcysteine on ethanol-induced hepatotoxicity in rats fed via total enteral nutrition. <i>Free Radical Biology and Medicine</i> , <b>2005</b> , 39, 619-30	7.8	87
172	Novel extrahepatic cytochrome P450s. <i>Toxicology and Applied Pharmacology</i> , <b>2005</b> , 207, 57-61	4.6	83
171	The human genome project and novel aspects of cytochrome P450 research. <i>Toxicology and Applied Pharmacology</i> , <b>2005</b> , 207, 52-6	4.6	95
170	Transcriptional regulation of the human CYP2A6 gene. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2005</b> , 313, 814-22	4.7	41
169	Characterization and partial purification of the rat and human enzyme systems active in the reduction of N-hydroxymelagatran and benzamidoxime. <i>Drug Metabolism and Disposition</i> , <b>2005</b> , 33, 570-8	4	30
168	Characterization of common CYP1B1 variants with different capacity for benzo[a]pyrene-7,8-dihydrodiol epoxide formation from benzo[a]pyrene. <i>Cancer Research</i> , <b>2005</b> , 65, 5105-11	10.1	43
167	A novel polymorphic cytochrome P450 formed by splicing of CYP3A7 and the pseudogene CYP3AP1. <i>Journal of Biological Chemistry</i> , <b>2005</b> , 280, 28324-31	5.4	20
166	Different structural requirements of the ligand binding domain of the aryl hydrocarbon receptor for high- and low-affinity ligand binding and receptor activation. <i>Molecular Pharmacology</i> , <b>2004</b> , 65, 416-23	4.3	65
165	Use of molecular simulation for mapping conformational CYP2E1 epitopes. <i>Journal of Biological Chemistry</i> , <b>2004</b> , 279, 50949-55	5.4	15
164	Differentiation of human hepatoma cells during confluence as revealed by gene expression profiling. <i>Biochemical Pharmacology</i> , <b>2004</b> , 67, 1249-58	6	22

163	Hepatic expression of multiple acute phase proteins and down-regulation of nuclear receptors after acute endotoxin exposure. <i>Biochemical Pharmacology</i> , <b>2004</b> , 67, 1389-97	6	70
162	Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , <b>2004</b> , 369, 89-104	3.4	235
161	A nicotine C-oxidase gene (CYP2A6) polymorphism important for promoter activity. <i>Human Mutation</i> , <b>2004</b> , 23, 258-66	4.7	28
160	Association of metabolic gene polymorphisms with tobacco consumption in healthy controls. <i>International Journal of Cancer</i> , <b>2004</b> , 110, 266-70	7.5	20
159	Characterization and tissue distribution of a novel human cytochrome P450-CYP2U1. <i>Biochemical and Biophysical Research Communications</i> , <b>2004</b> , 315, 679-85	3.4	53
158	Lack of sexual dimorphism in alcohol-induced liver damage (ALD) in rats treated chronically with ethanol-containing low carbohydrate diets: The role of ethanol metabolism and endotoxin. <i>Life Sciences</i> , <b>2004</b> , 75, 469-83	6.8	16
157	Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. <i>Trends in Pharmacological Sciences</i> , <b>2004</b> , 25, 193-200	13.2	488
156	Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. <i>American Journal of Clinical Nutrition</i> , <b>2004</b> , 79, 935-45	7	724
155	Alcoholic liver disease in rats fed ethanol as part of oral or intragastric low-carbohydrate liquid diets. <i>Experimental Biology and Medicine</i> , <b>2004</b> , 229, 351-60	3.7	32
154	Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. <i>Molecular Pharmacology</i> , <b>2003</b> , 64, 659-69	4.3	141
153	Pooled analysis of the CYP1A1 exon 7 polymorphism and lung cancer (United States). <i>Cancer Causes and Control</i> , <b>2003</b> , 14, 339-46	2.8	83
152	Xanthine oxidase activity is influenced by environmental factors in Ethiopians. <i>European Journal of Clinical Pharmacology</i> , <b>2003</b> , 59, 533-6	2.8	25
151	CYP1A1 T3801 C polymorphism and lung cancer: a pooled analysis of 2451 cases and 3358 controls. <i>International Journal of Cancer</i> , <b>2003</b> , 104, 650-7	7.5	121
150	Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. <i>Drug Metabolism and Disposition</i> , <b>2003</b> , 31, 755-61	4	196
149	Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems. <i>Drug Metabolism and Disposition</i> , <b>2003</b> , 31, 1093-102	4	72
148	Catechol-O-methyltransferase gene polymorphism and post-menopausal breast cancer risk. <i>Carcinogenesis</i> , <b>2003</b> , 24, 681-7	4.6	42
147	GYKI-47261, a new AMPA [2-amino-3-(3-hydroxymethylisoxazole-4-yl)propionic acid] antagonist, is a CYP2E1 inducer. <i>Drug Metabolism and Disposition</i> , <b>2003</b> , 31, 1310-4	4	6
146	Mechanisms of down-regulation of CYP2E1 expression by inflammatory cytokines in rat hepatoma cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2003</b> , 304, 1048-54	4.7	60

145	Cytochrome P450 1B1 gene polymorphisms and postmenopausal breast cancer risk. <i>Carcinogenesis</i> , <b>2003</b> , 24, 1533-9	4.6	59
144	Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity. <i>Human Mutation</i> , <b>2002</b> , 20, 275-83	4.7	85
143	The neuroprotective agents chlomethiazole and SB203580 inhibit IL-1beta signalling but not its biosynthesis in rat cortical glial cells. <i>Journal of Neurochemistry</i> , <b>2002</b> , 83, 727-37	6	18
142	Polymorphism of cytochrome P450 and xenobiotic toxicity. <i>Toxicology</i> , <b>2002</b> , 181-182, 447-52	4.4	77
141	The African-specific CYP2D617 allele encodes an enzyme with changed substrate specificity. <i>Clinical Pharmacology and Therapeutics</i> , <b>2002</b> , 71, 77-88	6.1	61
140	Microsomal epoxide hydrolase polymorphisms and lung cancer risk: a quantitative review. <i>Biomarkers</i> , <b>2002</b> , 7, 230-41	2.6	61
139	Meta- and pooled analyses of the effects of glutathione S-transferase M1 polymorphisms and smoking on lung cancer risk. <i>Carcinogenesis</i> , <b>2002</b> , 23, 1343-50	4.6	228
138	Functional analysis of six different polymorphic CYP1B1 enzyme variants found in an Ethiopian population. <i>Molecular Pharmacology</i> , <b>2002</b> , 61, 586-94	4.3	107
137	Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden. <i>Pharmacogenetics and Genomics</i> , <b>2002</b> , 12, 375-83		73
136	Hemin-mediated restoration of allylisopropylacetamide-inactivated CYP2B1: a role for glutathione and GRP94 in the heme-protein assembly. <i>Archives of Biochemistry and Biophysics</i> , <b>2002</b> , 408, 58-68	4.1	10
135	Characterization of the CYP2D6*29 allele commonly present in a black Tanzanian population causing reduced catalytic activity. <i>Pharmacogenetics and Genomics</i> , <b>2001</b> , 11, 417-27		67
134	Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. <i>British Journal of Clinical Pharmacology</i> , <b>2001</b> , 52, 447-50	3.8	154
133	The Ubiquitin-Proteasome 26s Pathway in Liver Cell Protein Turnover: Effect of Ethanol and Drugs. <i>Alcoholism: Clinical and Experimental Research</i> , <b>2001</b> , 25, 225S-229S	3.7	21
132	Ethanol and Oxidative Stress. <i>Alcoholism: Clinical and Experimental Research</i> , <b>2001</b> , 25, 237S-243S	3.7	87
131	Identification and characterization of a mitochondrial targeting signal in rat cytochrome P450 2E1 (CYP2E1). <i>Journal of Biological Chemistry</i> , <b>2001</b> , 276, 11317-22	5.4	39
130	Genetic variability in susceptibility and response to toxicants. <i>Toxicology Letters</i> , <b>2001</b> , 120, 259-68	4.4	58
129	Identification and tissue distribution of the novel human cytochrome P450 2S1 (CYP2S1). <i>Biochemical and Biophysical Research Communications</i> , <b>2001</b> , 281, 529-35	3.4	98
128	Cloning and tissue distribution of a novel human cytochrome p450 of the CYP3A subfamily, CYP3A43. <i>Biochemical and Biophysical Research Communications</i> , <b>2001</b> , 281, 1349-55	3.4	149

127	Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity. <i>Biochemical and Biophysical Research Communications</i> , <b>2001</b> , 284, 455-60	3.4	130
126	The importance of residues in substrate recognition site 3 for the catalytic function of CYP2D25 (vitamin D 25-hydroxylase). <i>Biochemical and Biophysical Research Communications</i> , <b>2001</b> , 288, 1059-63	3.4	10
125	Genetic and environmental causes for interindividual variability in drug pharmacokinetics. <i>International Congress Series</i> , <b>2001</b> , 1220, 175-186		1
124	Integration of In Vitro Approaches to Predict Drug Metabolism and Interaction in Man: An EU Validation Project. <i>ATLA Alternatives To Laboratory Animals</i> , <b>2001</b> , 29, 305-306	2.1	2
123	The ubiquitin-proteasome 26s pathway in liver cell protein turnover: effect of ethanol and drugs. <i>Alcoholism: Clinical and Experimental Research</i> , <b>2001</b> , 25, 225S-229S	3.7	7
122	Ethanol and oxidative stress. <i>Alcoholism: Clinical and Experimental Research</i> , <b>2001</b> , 25, 237S-243S	3.7	36
121	Neuroprotective agent chlormethiazole attenuates c-fos, c-jun, and AP-1 activation through inhibition of p38 MAP kinase. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2000</b> , 20, 1077-88	7.3	42
120	Effect of starvation and chlormethiazole on cytochrome P450s of rat nasal mucosa. <i>Biochemical Pharmacology</i> , <b>2000</b> , 59, 1425-32	6	32
119	Molecular basis for the transport of cytochrome P450 2E1 to the plasma membrane. <i>Journal of Biological Chemistry</i> , <b>2000</b> , 275, 17130-5	5.4	51
118	Identification of CYP4F8 in human seminal vesicles as a prominent 19-hydroxylase of prostaglandin endoperoxides. <i>Journal of Biological Chemistry</i> , <b>2000</b> , 275, 21844-9	5.4	63
117	Characterization and functional analysis of two common human cytochrome P450 1B1 variants. <i>Archives of Biochemistry and Biophysics</i> , <b>2000</b> , 378, 175-81	4.1	50
116	Cyclic expression of class I alcohol dehydrogenase in male rats treated with ethanol. <i>Biochemical and Biophysical Research Communications</i> , <b>2000</b> , 274, 684-8	3.4	29
115	The effect of ethanol-induced cytochrome p4502E1 on the inhibition of proteasome activity by alcohol. <i>Biochemical and Biophysical Research Communications</i> , <b>2000</b> , 279, 23-9	3.4	105
114	Kupffer cell inactivation alleviates ethanol-induced steatosis and CYP2E1 induction but not inflammatory responses in rat liver. <i>Journal of Hepatology</i> , <b>2000</b> , 32, 900-10	13.4	61
113	Autoantibodies against cytochromes P-4502E1 and P-4503A in alcoholics. <i>Molecular Pharmacology</i> , <b>1999</b> , 55, 223-33	4.3	58
112	Metabolism of benzene in human liver microsomes: individual variations in relation to CYP2E1 expression. <i>Archives of Toxicology</i> , <b>1999</b> , 73, 33-40	5.8	46
111	Structural and mechanistic aspects of transcriptional induction of cytochrome P450 1A1 by benzimidazole derivatives in rat hepatoma H4IIE cells. <i>FEBS Journal</i> , <b>1999</b> , 261, 66-71		29
110	Effect of chronic coadministration of endotoxin and ethanol on rat liver pathology and proinflammatory and anti-inflammatory cytokines. <i>Hepatology</i> , <b>1999</b> , 29, 1503-10	11.2	97

109	Genetic polymorphism of xenobiotic metabolizing enzymes among Chinese lung cancer patients. <i>International Journal of Cancer</i> , <b>1999</b> , 81, 325-9	7.5	74
108	Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. <i>Trends in Pharmacological Sciences</i> , <b>1999</b> , 20, 342-9	13.2	411
107	Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. <i>Gene</i> , <b>1999</b> , 226, 327-38	3.8	131
106	Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. <i>FEBS Letters</i> , <b>1999</b> , 448, 105-10	3.8	147
105	A soluble NH(2)-terminally truncated catalytically active form of rat cytochrome P450 2E1 targeted to liver mitochondria(1). <i>FEBS Letters</i> , <b>1999</b> , 460, 309-14	3.8	48
104	Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism. <i>FEBS Letters</i> , <b>1999</b> , 460, 321-7	3.8	135
103	Genetic epidemiology of environmental toxicity and cancer susceptibility: human allelic polymorphisms in drug-metabolizing enzyme genes, their functional importance, and nomenclature issues. <i>Drug Metabolism Reviews</i> , <b>1999</b> , 31, 467-87	7	83
102	Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. <i>Biochemical and Biophysical Research Communications</i> , <b>1999</b> , 254, 628-31	3.4	215
101	Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5'upstream regulatory region. <i>Biochemical and Biophysical Research Communications</i> , <b>1999</b> , 259, 201-5	3.4	262
100	Structural and functional characterization of the 5'flanking region of the rat and human cytochrome P450 2E1 genes: identification of a polymorphic repeat in the human gene. <i>Biochemical and Biophysical Research Communications</i> , <b>1999</b> , 263, 286-93	3.4	77
99	Relationship between cytochrome P450 catalytic cycling and stability: fast degradation of ethanol-inducible cytochrome P450 2E1 (CYP2E1) in hepatoma cells is abolished by inactivation of its electron donor NADPH-cytochrome P450 reductase. <i>Biochemical Journal</i> , <b>1999</b> , 340, 453-458	3.8	59
98	ROLE OF CYTOCHROME P450 ENZYMES IN ALCOHOL LIVER DISEASE PATHOGENESIS. <i>Alcoholism: Clinical and Experimental Research</i> , <b>1998</b> , 22, 739-740	3.7	2
97	CYTOCHROME P450 2E1, HYDROXYETHYL FREE RADICALS, AND IMMUNE REACTIONS ASSOCIATED WITH ALCOHOLIC LIVER DISEASE. <i>Alcoholism: Clinical and Experimental Research</i> , <b>1998</b> , 22, 740-742	3.7	6
96	A stress-inducible rat liver endoplasmic reticulum protein, ERp29. <i>FEBS Journal</i> , <b>1998</b> , 251, 304-13		78
95	Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. <i>Hepatology</i> , <b>1998</b> , 27, 128-33	11.2	496
94	Zonated expression of cytokines in rat liver: effect of chronic ethanol and the cytochrome P450 2E1 inhibitor, chlormethiazole. <i>Hepatology</i> , <b>1998</b> , 27, 1304-10	11.2	79
93	Oligomerization properties of ERp29, an endoplasmic reticulum stress protein. <i>FEBS Letters</i> , <b>1998</b> , 431, 322-6	3.8	36
92	Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase. <i>FEBS Letters</i> , <b>1998</b> , 438, 201-5	3.8	106



91	Expression and distribution of cytochrome P450 enzymes in male rat kidney: effects of ethanol, acetone and dietary conditions. <i>Biochemical Pharmacology</i> , <b>1998</b> , 55, 123-9	6	53
90	Signal transduction-mediated activation of the aryl hydrocarbon receptor in rat hepatoma H4IIE cells. <i>Journal of Biological Chemistry</i> , <b>1997</b> , 272, 31755-63	5.4	93
89	Lipid peroxidation, CYP2E1 and arachidonic acid metabolism in alcoholic liver disease in rats. <i>Journal of Nutrition</i> , <b>1997</b> , 127, 907S-911S	4.1	71
88	Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. <i>Pharmacogenetics and Genomics</i> , <b>1997</b> , 7, 187-91		181
87	Pretranslational and posttranslational regulation of rat hepatic CYPs 3A2 and 2E1 by disulfiram. <i>Biochemical Pharmacology</i> , <b>1997</b> , 54, 1323-9	6	15
86	Detection of cytochrome P4503A (CYP3A) in human hepatic stellate cells. <i>Biochemical and Biophysical Research Communications</i> , <b>1997</b> , 238, 420-4	3.4	15
85	Characterization of a human glutathione S-transferase mu cluster containing a duplicated GSTM1 gene that causes ultrarapid enzyme activity. <i>Molecular Pharmacology</i> , <b>1997</b> , 52, 958-65	4.3	97
84	A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function. <i>Molecular Pharmacology</i> , <b>1997</b> , 52, 1034-40	4.3	124
83	Selective fast degradation of cytochrome P-450 2E1 in serum-deprived hepatoma cells by a mechanism sensitive to inhibitors of vesicular transport. <i>FEBS Journal</i> , <b>1997</b> , 247, 37-43		12
82	Genetic polymorphism of human cytochrome P450 2E1. <i>Methods in Enzymology</i> , <b>1996</b> , 272, 218-25	1.7	13
81	Expression, catalytic activity, and inducibility of cytochrome P450 2E1 (CYP2E1) in the rat central nervous system. <i>Journal of Neurochemistry</i> , <b>1996</b> , 67, 2066-73	6	50
80	Effects of diet and ethanol on the expression and localization of cytochromes P450 2E1 and P450 2C7 in the colon of male rats. <i>Biochemical Pharmacology</i> , <b>1996</b> , 51, 61-9	6	40
79	Enzyme-specific transport of rat liver cytochrome P450 to the Golgi apparatus. <i>Archives of Biochemistry and Biophysics</i> , <b>1996</b> , 333, 459-65	4.1	49
78	High rates of substrate hydroxylation by human cytochrome P450 3A4 in reconstituted membranous vesicles: influence of membrane charge. <i>Biochemical and Biophysical Research Communications</i> , <b>1996</b> , 221, 318-22	3.4	50
77	Hepatotoxicity induced by iron overload and alcohol. Studies on the role of chelatable iron, cytochrome P450 2E1 and lipid peroxidation. <i>Journal of Hepatology</i> , <b>1996</b> , 25, 538-46	13.4	46
76	Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. <i>Pharmacogenetics and Genomics</i> , <b>1996</b> , 6, 441-7		92
75	PCR-based genotyping for duplicated and deleted CYP2D6 genes. <i>Pharmacogenetics and Genomics</i> , <b>1996</b> , 6, 351-5		91
74	The role of CYP2E1 and 2B1 in metabolic activation of benzene derivatives. <i>Archives of Toxicology</i> , <b>1996</b> , 71, 45-56	5.8	48

73	A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. <i>British Journal of Clinical Pharmacology</i> , <b>1996</b> , 42, 713-9	3.8	168
72	Effect of carrageenan-induced granuloma on hepatic cytochrome P-450 isozymes in rats. <i>Inflammation</i> , <b>1995</b> , 19, 143-56	5.1	10
71	Induction mechanisms of cytochrome P450 2E1 in liver: interplay between ethanol treatment and starvation. <i>Biochemical Pharmacology</i> , <b>1995</b> , 50, 155-61	6	57
70	Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe. <i>Clinical Pharmacology and Therapeutics</i> , <b>1995</b> , 57, 656-61	6.1	77
69	Inhibition of CYP2E1 activity does not abolish pulsatile urine alcohol concentrations during chronic alcohol infusions. <i>FEBS Journal</i> , <b>1995</b> , 230, 914-9		12
68	Characterization of cytochrome P450 2E1 induction in a rat hepatoma FGC-4 cell model by ethanol. <i>Biochemical Pharmacology</i> , <b>1994</b> , 48, 1823-33	6	42
67	Induction, suppression and inhibition of multiple hepatic cytochrome P450 isozymes in the male rat and bobwhite quail ( <i>Colinus virginianus</i> ) by ergosterol biosynthesis inhibiting fungicides (EBIFs). <i>Biochemical Pharmacology</i> , <b>1994</b> , 48, 1953-65	6	98
66	Spin trapping of alcohol-derived radicals in microsomes and reconstituted systems by electron spin resonance. <i>Methods in Enzymology</i> , <b>1994</b> , 233, 117-27	1.7	19
65	Ethanol-inducible cytochrome P450 2E1: genetic polymorphism, regulation, and possible role in the etiology of alcohol-induced liver disease. <i>Alcohol</i> , <b>1993</b> , 10, 447-52	2.7	199
64	Pulsatile blood alcohol and CYP2E1 induction during chronic alcohol infusions in rats. <i>Alcohol</i> , <b>1993</b> , 10, 453-7	2.7	31
63	Genetic polymorphism of cytochrome P450 CYP2D6 in Zimbabwean population. <i>Pharmacogenetics and Genomics</i> , <b>1993</b> , 3, 275-80		47
62	Differential regulation of gelatinase B and tissue-type plasminogen activator expression in human Bowes melanoma cells. <i>International Journal of Cancer</i> , <b>1993</b> , 53, 395-400	7.5	26
61	Dehydrogenase-dependent metabolism of alcohols in gastric mucosa of deer mice lacking hepatic alcohol dehydrogenase. <i>Biochemical Pharmacology</i> , <b>1993</b> , 45, 1989-94	6	8
60	Acetone-dependent regulation of cytochromes P450 2E1 and P450 2B1 in rat nasal mucosa. <i>Biochemical Pharmacology</i> , <b>1993</b> , 46, 1945-51	6	28
59	Genetic polymorphism of cytochromes P450: interethnic differences and relationship to incidence of lung cancer. <i>Pharmacogenetics and Genomics</i> , <b>1992</b> , 2, 264-71		39
58	Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. <i>Clinical Pharmacology and Therapeutics</i> , <b>1992</b> , 51, 12-7	6.1	171
57	Effect of chronic hypoxia on detoxication enzymes in rat liver. <i>Biochemical Pharmacology</i> , <b>1992</b> , 43, 242-166		39
56	The microsomal monooxygenase system of regenerating liver. An examination of the role of estradiol in the demasculinization of drug metabolism produced by 2/3 partial hepatectomy. <i>Biochemical Pharmacology</i> , <b>1992</b> , 43, 567-73	6	11

55	Effects of dietary fat composition on activities of the microsomal ethanol oxidizing system and ethanol-inducible cytochrome P450 (CYP2E1) in the liver of rats chronically fed ethanol. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>1992</b> , 70, 347-51		54
54	Oxidoreduction of butanol in deermice ( <i>Peromyscus maniculatus</i> ) lacking hepatic cytosolic alcohol dehydrogenase. <i>FEBS Journal</i> , <b>1992</b> , 204, 353-7		10
53	Zonation of cytochrome P450 isozyme expression and induction in rat liver. <i>FEBS Journal</i> , <b>1992</b> , 204, 407-12		92
52	Effects of short-term ethanol and nutrition on the hepatic microsomal monooxygenase system in a model utilizing total enteral nutrition in the rat. <i>Alcoholism: Clinical and Experimental Research</i> , <b>1991</b> , 15, 693-9	3.7	44
51	Hydroxylation of salicylate as an assay for hydroxyl radicals: a cautionary note. <i>Free Radical Biology and Medicine</i> , <b>1991</b> , 10, 439-41	7.8	240
50	Acetone-regulated synthesis and degradation of cytochrome P450E1 and cytochrome P450B1 in rat liver [corrected]. <i>FEBS Journal</i> , <b>1991</b> , 198, 383-9		69
49	Effect of in vivo chromate, acetone and combined treatment on rat liver in vitro microsomal chromium(VI) reductive activity and on cytochrome P450 expression. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>1991</b> , 68, 456-63		6
48	Immunochemical localization and functional characterization of cytochrome P450IIE1 in rat hepatocyte foci and nodules. <i>Carcinogenesis</i> , <b>1991</b> , 12, 2353-6	4.6	4
47	Hormone controlled phosphorylation and degradation of CYP2B1 and CYP2E1 in isolated rat hepatocytes. <i>Biochemical and Biophysical Research Communications</i> , <b>1991</b> , 174, 37-42	3.4	33
46	Acetaldehyde as a substrate for ethanol-inducible cytochrome P450 (CYP2E1). <i>Biochemical and Biophysical Research Communications</i> , <b>1991</b> , 179, 689-94	3.4	85
45	Role of ethanol-inducible cytochrome P450 (P450IIE1) in catalysing the free radical activation of aliphatic alcohols. <i>Biochemical Pharmacology</i> , <b>1991</b> , 41, 1895-902	6	129
44	Transcriptional control of CYP2E1 in the perivenous liver region and during starvation. <i>Biochemical and Biophysical Research Communications</i> , <b>1990</b> , 173, 331-8	3.4	80
43	Differential rates of metabolic activation and detoxication of the food mutagen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine by different cytochrome P450 enzymes. <i>Carcinogenesis</i> , <b>1990</b> , 11, 489-92	4.6	116
42	Human liver microsomal cytochrome P-450IIE1. Immunological evaluation of its contribution to microsomal ethanol oxidation, carbon tetrachloride reduction and NADPH oxidase activity. <i>Biochemical Pharmacology</i> , <b>1989</b> , 38, 689-93	6	67
41	Rat liver microsomal NADPH-supported oxidase activity and lipid peroxidation dependent on ethanol-inducible cytochrome P-450 (P-450IIE1). <i>Biochemical Pharmacology</i> , <b>1989</b> , 38, 1313-9	6	461
40	Protein kinase C-dependent phosphorylation of profilin is specifically stimulated by phosphatidylinositol bisphosphate (PIP2). <i>Biochemical and Biophysical Research Communications</i> , <b>1988</b> , 150, 526-31	3.4	45
39	Ligand-dependent maintenance of ethanol-inducible cytochrome P-450 in primary rat hepatocyte cell cultures. <i>Biochemical and Biophysical Research Communications</i> , <b>1988</b> , 150, 436-43	3.4	155
38	Cytochrome P-450-dependent oxidase activity and hydroxyl radical production in micellar and membranous types of reconstituted systems. <i>Biochemical Pharmacology</i> , <b>1988</b> , 37, 1383-9	6	28

37	Centrilobular expression of ethanol-inducible cytochrome P-450 (IIE1) in rat liver. <i>Biochemical and Biophysical Research Communications</i> , <b>1988</b> , 157, 55-60	3.4	166
36	H <sub>2</sub> O <sub>2</sub> activates CD11b/CD18-dependent cell adhesion. <i>Biochemical and Biophysical Research Communications</i> , <b>1988</b> , 157, 443-9	3.4	43
35	Phorbol-ester-induced stable changes in the regulation of DNA synthesis and intracellular pH are accompanied by altered expression of protein kinase C in the monoblastoid cell line U-937. <i>International Journal of Cancer</i> , <b>1988</b> , 42, 284-8	7.5	
34	Modulation of the substrate specificity of purified human protein kinase C by its activators. <i>Acta Chemica Scandinavica</i> , <b>1987</b> , 41, 174-9		5
33	Mechanisms of lipid peroxidation dependent upon cytochrome P-450 LM2. <i>FEBS Journal</i> , <b>1986</b> , 158, 195-201		38
32	Activation of protein kinase C by lipoxin A and other eicosanoids. Intracellular action of oxygenation products of arachidonic acid. <i>Biochemical and Biophysical Research Communications</i> , <b>1986</b> , 134, 1215-22	3.4	202
31	Hydroxylation of acetone by ethanol- and acetone-inducible cytochrome P-450 in liver microsomes and reconstituted membranes. <i>FEBS Letters</i> , <b>1986</b> , 196, 59-64	3.8	46
30	Metabolism of n-pentane by ethanol-inducible cytochrome P-450 in liver microsomes and reconstituted membranes. <i>FEBS Journal</i> , <b>1986</b> , 161, 303-8		37
29	Cytochrome P-450-dependent fragmentation of DNA in reconstituted membranes. <i>Acta Pharmacologica Et Toxicologica</i> , <b>1985</b> , 56, 69-74		1
28	Rapid effects of phorbol esters on isolated rat adipocytes. Relationship to the action of protein kinase C. <i>FEBS Journal</i> , <b>1985</b> , 148, 407-12		41
27	Insulin-stimulated protein synthesis in adipocytes. Enhanced rate of initiation associated with increased phosphorylation of ribosomal protein S6. <i>FEBS Journal</i> , <b>1985</b> , 151, 97-100		22
26	Carbon tetrachloride-induced lipid peroxidation dependent on an ethanol-inducible form of rabbit liver microsomal cytochrome P-450. <i>FEBS Letters</i> , <b>1985</b> , 183, 265-9	3.8	176
25	Characterization of calcium and phospholipid dependent protein kinase in isolated rat adipocytes. <i>Acta Chemica Scandinavica</i> , <b>1985</b> , 39, 219-26		11
24	Mechanism of rate control of the NADPH-dependent reduction of cytochrome P-450 by lipids in reconstituted phospholipid vesicles. <i>FEBS Journal</i> , <b>1984</b> , 144, 509-13		38
23	Cytochrome P-450-dependent lipid peroxidation in reconstituted membrane vesicles. <i>Biochemical Pharmacology</i> , <b>1984</b> , 33, 2521-3	6	28
22	Induction of the ethanol-inducible form of rabbit liver microsomal cytochrome P-450 by inhibitors of alcohol dehydrogenase. <i>Biochemical and Biophysical Research Communications</i> , <b>1984</b> , 124, 375-82	3.4	43
21	Reduction of cytochrome P-450 LM2 by NADPH in reconstituted phospholipid vesicles is dependent on membrane charge. <i>FEBS Journal</i> , <b>1983</b> , 134, 157-62		32
20	Interindividual variation in benzo(a)pyrene metabolism and composition of isoenzymes of cytochrome P-450 as revealed by SDS-gel electrophoresis of human liver microsomal fractions. <i>Acta Pharmacologica Et Toxicologica</i> , <b>1982</b> , 50, 251-60		11

19	Aniline is hydroxylated by the cytochrome P-450-dependent hydroxyl radical-mediated oxygenation mechanism. <i>Biochemical and Biophysical Research Communications</i> , <b>1982</b> , 106, 625-31	3.4	32
18	Cytochrome b5 as electron donor to rabbit liver cytochrome P-450LM2 in reconstituted phospholipid vesicles. <i>Biochemical and Biophysical Research Communications</i> , <b>1980</b> , 97, 582-6	3.4	81
17	Benzo(a)pyrene metabolism by purified forms of rabbit liver microsomal cytochrome P-450, cytochrome b5 and epoxide hydase in reconstituted phospholipid vesicles. <i>Biochemical and Biophysical Research Communications</i> , <b>1980</b> , 95, 431-9	3.4	14
16	Changes in steroid hormone metabolism in rat liver microsomes following administration of 2,3,7,8-tetrachlorodibenzo-p-dioxine (TCDD). <i>Biochemical Pharmacology</i> , <b>1979</b> , 28, 497-9	6	27
15	Bioactivation or inactivation of toxic compounds?. <i>Trends in Pharmacological Sciences</i> , <b>1979</b> , 1, 176-179	13.2	7
14	Protein amino acid analysis by an isotope ratio gas chromatography mass spectrometry computer technique. <i>Biomedical Mass Spectrometry</i> , <b>1979</b> , 6, 317-24		9
13	Qualitative alterations of cytochrome P-450 in mouse liver microsomes after administration of acrylamide and methylmethacrylate. <i>Acta Pharmacologica Et Toxicologica</i> , <b>1978</b> , 43, 299-305		8
12	Reconstitution of the liver microsomal hydroxylase system into liposomes. <i>FEBS Letters</i> , <b>1977</b> , 78, 72-6	3.8	46
11	Resolution of multiple forms of phenobarbital-induced liver microsomal cytochrome P-450 by electrofocusing on granulated gels. <i>FEBS Letters</i> , <b>1977</b> , 74, 103-6	3.8	11
10	The involvement of cytochrome P-450 in hepatic microsomal steroid hydroxylation reactions supported by sodium periodate, sodium chlorite, and organic hydroperoxides. <i>FEBS Journal</i> , <b>1976</b> , 61, 43-52		99
9	Multiple forms of cytochrome P-450 in rat-liver microsomes. Separation and some properties of different hydroxylases active on free and sulphoconjugated steroids. <i>FEBS Journal</i> , <b>1976</b> , 64, 35-43		35
8	Specific metabolic pathways of steroid sulfates in human liver microsomes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1976</b> , 43, 56-63	5.6	22
7	Partial feminization of hepatic steroid metabolism in male rats after neonatal administration of cyproterone acetate. <i>Journal of Endocrinology</i> , <b>1975</b> , 64, 267-75	4.7	3
6	Sodium periodate, sodium chloride, organic hydroperoxides, and H <sub>2</sub> O <sub>2</sub> as hydroxylating agents in steroid hydroxylation reactions catalyzed by partially purified cytochrome P-450. <i>Biochemical and Biophysical Research Communications</i> , <b>1975</b> , 66, 209-16	3.4	158
5	Neonatal androgenic programming of hepatic steroid metabolism in rats. <i>The Journal of Steroid Biochemistry</i> , <b>1975</b> , 6, 643-9		20
4	Sodium periodate, sodium chlorite, and organic hydroperoxides as hydroxylating agents in hepatic microsomal steroid hydroxylation reactions catalyzed by cytochrome P-450. <i>FEBS Letters</i> , <b>1975</b> , 56, 161-3	3.8	49
3	Demonstration of a cytochrome P-450-dependent steroid 15beta-hydroxylase in <i>Bacillus megaterium</i> . <i>Biochemical and Biophysical Research Communications</i> , <b>1975</b> , 66, 1414-23	3.4	60
2	Sex-specific 15-hydroxylation of sulpho-conjugated 5-androstane-3, 17-diol in liver microsomes from female rats. <i>FEBS Letters</i> , <b>1973</b> , 31, 292-6	3.8	12

1 A unifying model to predict variable drug response for personalised medicine

8